Paul Andrew Cohen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paul Andrew Cohen has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Michael Friedlander
Prince of Wales Hospital and Royal Hospital for Women Randwick, Sydney, Australia
26 shared publications - Yee Leung
Department of Gynaecological Oncology, King Edward Memorial Hospital, Subiaco, WA, Australia
24 shared publications Jason Tan
St John of God Hospital Subiaco Western Australia Australia
23 shared publications- Martin Köbel
Department of Pathology and Laboratory Medicine, University of Calgary
23 shared publications - Lyndal Anderson
Royal Prince Alfred Hospital Camperdown NSW Australia
22 shared publications - Anna DeFazio
The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia
21 shared publications
Latest Publications
- Open Access
Spatial transcriptomics reveals tumour cell-intrinsic and microenvironmental features associated with survival in high-grade serous ovarian carcinoma
High-grade serous ovarian carcinoma (HGSOC) is the most common form of ovarian carcinoma and accounts for the majority of deaths from the disease, with fewer than half of patients surviving five years after diagnosis. Bulk transcriptomic profiling has identified molecular subtypes and gene-expression signatures associated with shorter or longer survival. However, because bulk profiling measures a composite of tumour and microenvironmental gene expression, the cellular origins of these signatures and their relationship to the tumour microenvironment remain unresolved. To address this, we applied Xenium spatial transcriptomics to treatment-naive HGSOC tumours from 122 patients using a custom 480-gene panel designed to measure tumour-intrinsic gene expression and distinguish immune and stromal cell populations in the surrounding microenvironment. Analysis of tumour-intrinsic gene expression identified 61 genes nominally associated with overall survival, from which Elastic-Net modelling prioritised five genes associated with longer survival and nine associated with shorter survival. Notably, 46 of the 61 associations did not reach the nominal significance threshold when expression was instead aggregated across all cells from the same patients, highlighting how whole-tissue expression can obscure tumour-cell-specific survival associations. Complementary analysis of tumour-proximal cell populations revealed that multiple immune populations were associated with longer survival, whereas two fibroblast populations were associated with shorter survival. Integrating these analyses revealed that survival-associated tumour-intrinsic gene expression was correlated with the abundance of neighbouring immune and stromal populations that were themselves associated with survival. Pairwise Cox regression demonstrated substantial overlap in the prognostic information captured by these features, while analysis of individual gene-cell combinations showed that survival associations differed according to the abundance of neighbouring populations. Consensus clustering further identified four patient groups with distinct combinations of tumour-intrinsic expression and microenvironmental composition, broadly separating patients with longer and shorter survival. Together, this cohort-scale spatial analysis identifies tumour-intrinsic and microenvironmental features associated with HGSOC survival and reveals how their correlated patterns and combined associations relate to patient outcome.
Open AccessSpatial transcriptomics reveals tumour cell-intrinsic and microenvironmental features associated with survival in high-grade serous ovarian carcinoma
High-grade serous ovarian carcinoma (HGSOC) is the most common form of ovarian carcinoma and accounts for the majority of deaths from the disease, with fewer than half of patients surviving five years after diagnosis. Bulk transcriptomic profiling has identified molecular subtypes and gene-expression signatures associated with shorter or longer survival. However, because bulk profiling measures a composite of tumour and microenvironmental gene expression, the cellular origins of these signatures and their relationship to the tumour microenvironment remain unresolved. To address this, we applied Xenium spatial transcriptomics to treatment-naive HGSOC tumours from 122 patients using a custom 480-gene panel designed to measure tumour-intrinsic gene expression and distinguish immune and stromal cell populations in the surrounding microenvironment. Analysis of tumour-intrinsic gene expression identified 61 genes nominally associated with overall survival, from which Elastic-Net modelling prioritised five genes associated with longer survival and nine associated with shorter survival. Notably, 46 of the 61 associations did not reach the nominal significance threshold when expression was instead aggregated across all cells from the same patients, highlighting how whole-tissue expression can obscure tumour-cell-specific survival associations. Complementary analysis of tumour-proximal cell populations revealed that multiple immune populations were associated with longer survival, whereas two fibroblast populations were associated with shorter survival. Integrating these analyses revealed that survival-associated tumour-intrinsic gene expression was correlated with the abundance of neighbouring immune and stromal populations that were themselves associated with survival. Pairwise Cox regression demonstrated substantial overlap in the prognostic information captured by these features, while analysis of individual gene-cell combinations showed that survival associations differed according to the abundance of neighbouring populations. Consensus clustering further identified four patient groups with distinct combinations of tumour-intrinsic expression and microenvironmental composition, broadly separating patients with longer and shorter survival. Together, this cohort-scale spatial analysis identifies tumour-intrinsic and microenvironmental features associated with HGSOC survival and reveals how their correlated patterns and combined associations relate to patient outcome.
- Open Access
- 14 September 2026
- Published by CSIRO Publishing in Public Health Research and Practice
- Vol. 36 (3)
Using administrative health data to ascertain ovarian cancer treatment information in Australia: a validation against medical records
Objectives: Understanding patterns of cancer care is important for improving patient safety and reducing inequity. Linked administrative datasets offer a cost-efficient alternative to medical chart abstraction, but the information may not be as comprehensive and accurate. Our aim was to determine the validity of using linked administrative data to identify ovarian cancer primary treatment in Australia, using data from medical charts for comparison. Methods: We used data from the Ovarian cancer Prognosis And Lifestyle study, a national prospective cohort study including women diagnosed with ovarian cancer from 2012 to 2015. Treatment information collected via medical records was used as the reference standard. Linked administrative data were obtained from national (Medicare Benefits Schedule, Pharmaceutical Benefits Scheme) and state/territory (hospital admitted patient data collections) data linkage units. The data were partitioned into training (60%, n = 413) and validation (40%, n = 271) datasets. Initial definitions were developed and further refined using the training set and based on clinical advice. The final definitions were assessed using the validation set. Sensitivity, specificity, negative predictive value, positive predictive value and kappa were calculated for receipt of treatment, whereas agreement was assessed for dates and continuous measures. Results: Sensitivity and specificity were high for receipt of chemotherapy (99%, 100%), cytoreductive surgery (97%, 100%), platinum-based chemotherapy (97%, 100%), taxane-based chemotherapy (98%, 88%), intra-peritoneal chemotherapy (93%, 99%) and whether chemotherapy was given in the adjuvant setting (100%, 90%). Agreement for treatment dates was high for surgery (exact agreement 90%, 97% ±7 days) and first chemotherapy (85%, 96% ±7 days). Agreement was moderately high for end of primary chemotherapy (72%, 82% ±7 days), number of chemotherapy cycles (65%, 89% ±1 cycle) and chemotherapy regimen (86%). Conclusions: Linked administrative data can provide accurate information on core aspects of ovarian cancer treatment when there are barriers to accessing patient medical records.
- 14 September 2026
- Published by CSIRO Publishing in Public Health Research and Practice
- Vol. 36 (3)
Open AccessUsing administrative health data to ascertain ovarian cancer treatment information in Australia: a validation against medical records
Objectives: Understanding patterns of cancer care is important for improving patient safety and reducing inequity. Linked administrative datasets offer a cost-efficient alternative to medical chart abstraction, but the information may not be as comprehensive and accurate. Our aim was to determine the validity of using linked administrative data to identify ovarian cancer primary treatment in Australia, using data from medical charts for comparison. Methods: We used data from the Ovarian cancer Prognosis And Lifestyle study, a national prospective cohort study including women diagnosed with ovarian cancer from 2012 to 2015. Treatment information collected via medical records was used as the reference standard. Linked administrative data were obtained from national (Medicare Benefits Schedule, Pharmaceutical Benefits Scheme) and state/territory (hospital admitted patient data collections) data linkage units. The data were partitioned into training (60%, n = 413) and validation (40%, n = 271) datasets. Initial definitions were developed and further refined using the training set and based on clinical advice. The final definitions were assessed using the validation set. Sensitivity, specificity, negative predictive value, positive predictive value and kappa were calculated for receipt of treatment, whereas agreement was assessed for dates and continuous measures. Results: Sensitivity and specificity were high for receipt of chemotherapy (99%, 100%), cytoreductive surgery (97%, 100%), platinum-based chemotherapy (97%, 100%), taxane-based chemotherapy (98%, 88%), intra-peritoneal chemotherapy (93%, 99%) and whether chemotherapy was given in the adjuvant setting (100%, 90%). Agreement for treatment dates was high for surgery (exact agreement 90%, 97% ±7 days) and first chemotherapy (85%, 96% ±7 days). Agreement was moderately high for end of primary chemotherapy (72%, 82% ±7 days), number of chemotherapy cycles (65%, 89% ±1 cycle) and chemotherapy regimen (86%). Conclusions: Linked administrative data can provide accurate information on core aspects of ovarian cancer treatment when there are barriers to accessing patient medical records.
- 15 May 2026
- Published by Wiley in The Journal of Pathology
- Vol. 269 (4-5) , 446-461
Identifying therapeutic targets in low‐grade serous ovarian carcinomas with no specific molecular profile
Low‐grade serous ovarian carcinoma (LGSOC) is a rare, indolent ovarian cancer subtype with limited effective therapies. Approximately 40% of cases lack canonical MAPK/ERK or PI3K/AKT/mTOR pathway alterations and are classified as having no specific molecular profile (NSMP). These patients have poor responses to chemotherapy, MEK inhibitors, and hormonal therapies, highlighting the need for alternative strategies. This study aimed to identify novel therapeutic targets in NSMP LGSOC. A high‐throughput drug screen of 3,436 compounds (including FDA‐approved, clinically tested, and investigational agents) was conducted across 12 LGSOC and one control ovarian epithelial cell line. EGFR inhibitors emerged as selective hits in NSMP cell lines and were further tested in two NSMP and two MAPK‐mutant lines in combination with standard‐of‐care chemotherapy agents, carboplatin and paclitaxel. EGFR expression was assessed using RNA sequencing, DNA methylation profiling, and immunohistochemistry in primary tumors, followed by survival analysis based on expression levels. Unsupervised clustering of drug response data revealed subtype‐specific vulnerabilities, with EGFR inhibitors showing marked cytotoxicity in all five NSMP lines (robust Z ‐score ≤ −2), and minimal activity in MAPK‐ and USP9X ‐mutant lines. EGFR inhibitors (avitinib, AV‐412) showed selective, low‐dose synergy with standard‐of‐care chemotherapy in NSMP models, with minimal and inconsistent effects in MAPK‐mutant lines. NSMP tumors showed elevated EGFR mRNA and EGFR protein expression, associated with poor survival, advanced disease stage, and peritoneal involvement, and inversely correlated with MAPK mutations. These findings position EGFR overexpression as a defining and targetable feature of NSMP LGSOC and support further preclinical validation of EGFR inhibitors as a treatment strategy for this understudied cancer subtype. © 2026 The Pathological Society of Great Britain and Ireland.
- 15 May 2026
- Published by Wiley in The Journal of Pathology
- Vol. 269 (4-5) , 446-461
Identifying therapeutic targets in low‐grade serous ovarian carcinomas with no specific molecular profile
Low‐grade serous ovarian carcinoma (LGSOC) is a rare, indolent ovarian cancer subtype with limited effective therapies. Approximately 40% of cases lack canonical MAPK/ERK or PI3K/AKT/mTOR pathway alterations and are classified as having no specific molecular profile (NSMP). These patients have poor responses to chemotherapy, MEK inhibitors, and hormonal therapies, highlighting the need for alternative strategies. This study aimed to identify novel therapeutic targets in NSMP LGSOC. A high‐throughput drug screen of 3,436 compounds (including FDA‐approved, clinically tested, and investigational agents) was conducted across 12 LGSOC and one control ovarian epithelial cell line. EGFR inhibitors emerged as selective hits in NSMP cell lines and were further tested in two NSMP and two MAPK‐mutant lines in combination with standard‐of‐care chemotherapy agents, carboplatin and paclitaxel. EGFR expression was assessed using RNA sequencing, DNA methylation profiling, and immunohistochemistry in primary tumors, followed by survival analysis based on expression levels. Unsupervised clustering of drug response data revealed subtype‐specific vulnerabilities, with EGFR inhibitors showing marked cytotoxicity in all five NSMP lines (robust Z ‐score ≤ −2), and minimal activity in MAPK‐ and USP9X ‐mutant lines. EGFR inhibitors (avitinib, AV‐412) showed selective, low‐dose synergy with standard‐of‐care chemotherapy in NSMP models, with minimal and inconsistent effects in MAPK‐mutant lines. NSMP tumors showed elevated EGFR mRNA and EGFR protein expression, associated with poor survival, advanced disease stage, and peritoneal involvement, and inversely correlated with MAPK mutations. These findings position EGFR overexpression as a defining and targetable feature of NSMP LGSOC and support further preclinical validation of EGFR inhibitors as a treatment strategy for this understudied cancer subtype. © 2026 The Pathological Society of Great Britain and Ireland.
- Open Access
- 1 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma
BRCA -associated homologous recombination deficiency (HRD) is present in ~50% of high-grade serous carcinomas (HGSC) and predicts sensitivity to platinum-based therapy. However, there is little understanding of why some patients with BRCA -deficient tumors experience poor outcomes. In a large HGSC cohort (n = 1389) including 282 individuals with pathogenic germline BRCA variants (g BRCA pv), residual disease after primary surgery has limited prognostic effect in g BRCA pv-carriers compared to non-carriers, and prognostic outcomes differ based on the mutation location within functional domains of the BRCA genes. Multi-omic profiling is performed on 154 tumors, enriched for patients with BRCA -deficient tumors that experienced short overall survival ( ≤ 3 years, n = 42). Patients with BRCA2 -deficient HGSC and loss of NF1 survive twice as long as those without NF1 loss, whereas PIK3CA , RAD21 and MYC amplification define BRCA2 -deficient HGSC with exceptionally short survival. Patients with BRCA1 -deficient HGSC and a more elevated HRD score survive significantly longer. BRCA1 -deficient tumors in short survivors have evidence of immunosuppressive c-kit signaling and EMT. Our findings confirm that outcome is not determined by BRCA status alone, but rather a combination of co-occurring genomic alterations, the extent of DNA repair deficiency, and the tumor-immune microenvironment.
- 1 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessClinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma
BRCA -associated homologous recombination deficiency (HRD) is present in ~50% of high-grade serous carcinomas (HGSC) and predicts sensitivity to platinum-based therapy. However, there is little understanding of why some patients with BRCA -deficient tumors experience poor outcomes. In a large HGSC cohort (n = 1389) including 282 individuals with pathogenic germline BRCA variants (g BRCA pv), residual disease after primary surgery has limited prognostic effect in g BRCA pv-carriers compared to non-carriers, and prognostic outcomes differ based on the mutation location within functional domains of the BRCA genes. Multi-omic profiling is performed on 154 tumors, enriched for patients with BRCA -deficient tumors that experienced short overall survival ( ≤ 3 years, n = 42). Patients with BRCA2 -deficient HGSC and loss of NF1 survive twice as long as those without NF1 loss, whereas PIK3CA , RAD21 and MYC amplification define BRCA2 -deficient HGSC with exceptionally short survival. Patients with BRCA1 -deficient HGSC and a more elevated HRD score survive significantly longer. BRCA1 -deficient tumors in short survivors have evidence of immunosuppressive c-kit signaling and EMT. Our findings confirm that outcome is not determined by BRCA status alone, but rather a combination of co-occurring genomic alterations, the extent of DNA repair deficiency, and the tumor-immune microenvironment.
- Open Access
- 30 March 2026
- Published by Springer Nature in Global Implementation Research and Applications
- Vol. 6 (3) , 553-567
Managing Menopause After Cancer: Perceived Enablers and Barriers to Use of an Online Stepped-Care Platform
Menopausal symptoms are common in cancer survivors, often affecting their daily lives. Despite available treatments, few have access to adequate symptom management. Novel approaches, such as those incorporating symptom assessment and tailored or stepped approaches, are needed. This study explored perceived enablers and barriers to using an online patient-driven stepped-care platform to screen for and manage menopausal symptoms. Women with a history of cancer were invited through partner organisations by email or social media. Participants completed semi-structured interview based on a theoretical domain framework and the capability, opportunity, and motivation-behavior model. Transcripts were coded into the 14 theoretical domains. Belief statements were analysed into themes and categorised as enablers or barriers. Twenty participants (aged 30–75) were interviewed. Most were Australian-born ( n = 18), held vocational training or bachelor’s degree ( n = 12), and were employed ( n = 11). The most common cancer experienced was breast ( n = 6), most had received chemotherapy ( n = 16), were pre-menopausal before treatment ( n = 13) and reported hot flushes or vaginal dryness ( n = 14 each). Twenty-eight themes were identified. Enablers included high confidence in using mobile technologies, a user-friendly platform, and their role as “cancer survivor” to self-manage symptoms. Barriers included low awareness of the stepped-care concept, patient-related comorbidities, and time constraints. The platform’s concept was viewed positively and as important, with high intention to use and follow recommended pathways. This study provides insights into factors that could influence survivors’ engagement with the platform. Findings will guide the prototype development.
- 30 March 2026
- Published by Springer Nature in Global Implementation Research and Applications
- Vol. 6 (3) , 553-567
Open AccessManaging Menopause After Cancer: Perceived Enablers and Barriers to Use of an Online Stepped-Care Platform
Menopausal symptoms are common in cancer survivors, often affecting their daily lives. Despite available treatments, few have access to adequate symptom management. Novel approaches, such as those incorporating symptom assessment and tailored or stepped approaches, are needed. This study explored perceived enablers and barriers to using an online patient-driven stepped-care platform to screen for and manage menopausal symptoms. Women with a history of cancer were invited through partner organisations by email or social media. Participants completed semi-structured interview based on a theoretical domain framework and the capability, opportunity, and motivation-behavior model. Transcripts were coded into the 14 theoretical domains. Belief statements were analysed into themes and categorised as enablers or barriers. Twenty participants (aged 30–75) were interviewed. Most were Australian-born ( n = 18), held vocational training or bachelor’s degree ( n = 12), and were employed ( n = 11). The most common cancer experienced was breast ( n = 6), most had received chemotherapy ( n = 16), were pre-menopausal before treatment ( n = 13) and reported hot flushes or vaginal dryness ( n = 14 each). Twenty-eight themes were identified. Enablers included high confidence in using mobile technologies, a user-friendly platform, and their role as “cancer survivor” to self-manage symptoms. Barriers included low awareness of the stepped-care concept, patient-related comorbidities, and time constraints. The platform’s concept was viewed positively and as important, with high intention to use and follow recommended pathways. This study provides insights into factors that could influence survivors’ engagement with the platform. Findings will guide the prototype development.
- 14 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500664
Quality Matters: Linking Patterns of Care to Ovarian Cancer Survival in a National Gynae-Oncology Registry
PURPOSE: Ovarian cancer (OC) is a leading cause of gynecologic cancer mortality, with poor survival rates for advanced-stage disease. Comprehensive national data detailing contemporary patterns of care remain scarce. This study uses data from Australia's National Gynae-Oncology Registry (NGOR) to delineate current patterns of care against clinical quality indicators (CQIs) and correlate adherence to these measures with overall survival (OS). METHODS: This prospective study analyzed NGOR data for women with newly diagnosed epithelial OC across 47 sites between April 2017 and March 2024. Adherence to 15 predefined CQIs was assessed. OS, adjusted for key prognostic factors (Eastern Cooperative Oncology Group, age, stage, comorbidity), was estimated using Cox proportional hazards regression. RESULTS: A total of 3,133 patients were included. In an adjusted multivariate analysis, significantly improved OS was associated with receiving first-line platinum-taxane doublet chemotherapy (hazard ratio [HR], 0.57 [95% CI, 0.47 to 0.68], P < .001), undergoing germline or somatic BRCA1/2 testing (HR, 0.66 [95% CI, 0.56 to 0.78], P < .001), and achieving no macroscopic residual disease after primary (HR, 0.48 [95% CI, 0.34 to 0.68], P < .001) or interval debulking surgery (HR, 0.56 [95% CI, 0.44 to 0.71], P < .001). Adjusted 5-year OS rates for International Federation of Gynecology and Obstetrics stages I, II, III, and IV were 87%, 76%, 42%, and 28%, respectively. CONCLUSION: This national registry reveals variations in CQI adherence. While survival for advanced-stage disease has improved, it remains suboptimal. Adherence to specific quality indicators—notably optimal surgical cytoreduction, standard first-line chemotherapy, and genetic testing—is significantly associated with improved survival. Continuous monitoring and targeted quality improvement initiatives are essential for enhancing survival for women with OC.
- 14 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500664
Quality Matters: Linking Patterns of Care to Ovarian Cancer Survival in a National Gynae-Oncology Registry
PURPOSE: Ovarian cancer (OC) is a leading cause of gynecologic cancer mortality, with poor survival rates for advanced-stage disease. Comprehensive national data detailing contemporary patterns of care remain scarce. This study uses data from Australia's National Gynae-Oncology Registry (NGOR) to delineate current patterns of care against clinical quality indicators (CQIs) and correlate adherence to these measures with overall survival (OS). METHODS: This prospective study analyzed NGOR data for women with newly diagnosed epithelial OC across 47 sites between April 2017 and March 2024. Adherence to 15 predefined CQIs was assessed. OS, adjusted for key prognostic factors (Eastern Cooperative Oncology Group, age, stage, comorbidity), was estimated using Cox proportional hazards regression. RESULTS: A total of 3,133 patients were included. In an adjusted multivariate analysis, significantly improved OS was associated with receiving first-line platinum-taxane doublet chemotherapy (hazard ratio [HR], 0.57 [95% CI, 0.47 to 0.68], P < .001), undergoing germline or somatic BRCA1/2 testing (HR, 0.66 [95% CI, 0.56 to 0.78], P < .001), and achieving no macroscopic residual disease after primary (HR, 0.48 [95% CI, 0.34 to 0.68], P < .001) or interval debulking surgery (HR, 0.56 [95% CI, 0.44 to 0.71], P < .001). Adjusted 5-year OS rates for International Federation of Gynecology and Obstetrics stages I, II, III, and IV were 87%, 76%, 42%, and 28%, respectively. CONCLUSION: This national registry reveals variations in CQI adherence. While survival for advanced-stage disease has improved, it remains suboptimal. Adherence to specific quality indicators—notably optimal surgical cytoreduction, standard first-line chemotherapy, and genetic testing—is significantly associated with improved survival. Continuous monitoring and targeted quality improvement initiatives are essential for enhancing survival for women with OC.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Kaplan–Meier curves of OS in (A) main tumor groups (n = 582)—MBOT, MOC, LGI, and UGI; (B) patients with MOC by FIGO stage (n = 184); (C) patients with MOC by pattern of invasion in all stages (n = 178); and (D) patients with stage I MOC (n = 134), by pattern of invasion.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Kaplan–Meier curves of OS in (A) main tumor groups (n = 582)—MBOT, MOC, LGI, and UGI; (B) patients with MOC by FIGO stage (n = 184); (C) patients with MOC by pattern of invasion in all stages (n = 178); and (D) patients with stage I MOC (n = 134), by pattern of invasion.